Industry

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients

– Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the six treated patients – The five longest treated patients exhibited elevated α-Gal A activity, ranging from nearly 3-fold to nearly 17-fold above mean normal, up to 15 months as at the last date of measurement – One patient … [Read more…]

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

Vivani will be traded under the new ticker (Nasdaq: VANI) LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc.(NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, … [Read more…]

The Worldwide Bioinformatics Industry is Expected to Reach $46.8 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bioinformatics – Market Insights, Competitive Landscape and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering. The global bioinformatics market was valued at USD 20.12 Billion in 2021, growing at a CAGR of 15.14% during the forecast period from 2022 to 2027 to reach USD 46.88 Billion by 2027. Companies Mentioned Agilent Technologies … [Read more…]

Insights on the Pharmaceutical Logistics Global Market to 2027 – US Is the Largest Exporter of Pharmaceutical Products by Air Transport – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Pharmaceutical Logistics Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering. The Global Pharmaceutical Logistics market size is expected to show an annual growth rate of approximately 5% during the forecast period 2022-2027. Companies Mentioned Deutsche Post DHL Kuehne + Nagel UPS (Marken) … [Read more…]

Thermo Fisher Scientific Launches CE-IVD (IVDD) Next-Generation Sequencing Test and Analysis Software to Expand Access to Precision Oncology Biomarker Testing

Oncomine Dx Express Test and Oncomine Reporter Dx informatics combine with Ion Torrent Genexus Dx System to deliver clinically relevant biomarker results in as little as one day CARLSBAD, Calif.–(BUSINESS WIRE)–Next-generation sequencing (NGS) is quickly becoming the platform of choice for tumor molecular profiling due to its ability to simultaneously report on multiple biomarkers. However, … [Read more…]

Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone

The Phase 2 trial for the treatment of NASH met its primary efficacy endpoint; PXL065-treated patients achieved statistically significant improvements in the relative decrease in liver fat content measured by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) at 36-weeks for all doses. Key secondary measures in PXL065-treated patients included a statistically significant improvement … [Read more…]

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

BEIJING & SAN DIEGO–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment … [Read more…]

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

BEIJING & SAN DIEGO–(BUSINESS WIRE)–#Biocytogen–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment … [Read more…]

Rapid Dose Therapeutics Confirms Delay in Filing Annual Financial Statements and Issuance of Failure-to-File Cease Trade Order

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, confirms that the Ontario Securities Commission (the “OSC”) has issued a failure to file cease trade order against the Company (“FTFCTO”) which orders that general trading, whether direct or indirect, by any person, of … [Read more…]

MultiPlan Earns Great Place to Work Certification™

94 percent of MultiPlan employees say that people of all cultures, abilities, and backgrounds are respected and valued at MultiPlan NEW YORK–(BUSINESS WIRE)–$MPLN #MPLN—MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a market-leading, technology-enabled provider of end-to-end healthcare cost management solutions, announced today its designation as a Great Place to Work-Certified™ company for 2022-2023. This distinction … [Read more…]